Identification

Name
Calcipotriol
Accession Number
DB02300  (EXPT02131)
Type
Small Molecule
Groups
Approved
Description

Calcipotriol (INN) or calcipotriene (USAN) is a sythetic derivative of calcitriol or Vitamin D.

Structure
Thumb
Synonyms
  • Calcipotriene
  • Calcipotriol
  • Daivonex
External IDs
MC 903 / MC-903
Product Ingredients
IngredientUNIICASInChI Key
Calcipotriol hydrateS7499TYY6G147657-22-5XBKHACNRWFKJNC-MANNPBRJSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
CalcipotrieneCream50 ug/gTopicalPrasco, Laboratories1996-10-01Not applicableUs
CalcipotrieneOintment50 ug/gTopicalPrasco, Laboratories2013-07-01Not applicableUs
DovonexCream50 ug/gTopicalWarner Chilcott2006-01-012017-06-29Us
DovonexCream50 ug/gTopicalPhysicians Total Care, Inc.2006-09-15Not applicableUs
DovonexCream50 ug/gTopicalLeo Pharma1996-10-01Not applicableUs
DovonexSolution.05 mg/mLTopicalWarner Chilcott2006-01-012017-06-29Us
DovonexSolution.05 mg/mLTopicalPhysicians Total Care, Inc.2009-08-12Not applicableUs
DovonexSolution.05 mg/mLTopicalLeo Pharma1997-06-012017-08-17Us
Dovonex - Crm 50mcg/gmCream50 mcgTopicalLeo Pharma1995-12-312016-03-11Canada
Dovonex Ont 50mcg/gmOintment50 mcgTopicalLeo Pharma1992-12-31Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
CalcipotrieneSolution.05 mg/mLTopicalE. Fougera & CO., A division of Fougera Pharmaceuticals Inc.2008-05-06Not applicableUs
CalcipotrieneSolution.05 mg/mLTopicalGw Pharmaceuticals Ltd.2011-04-04Not applicableUs
CalcipotrieneOintment.05 mg/gTopicalTaro Pharmaceuticals U.S.A., Inc.2010-03-24Not applicableUs
CalcipotrieneCream50 ug/gTopicalGlenmark Pharmaceuticals Inc.,Usa2015-06-10Not applicableUs
CalcipotrieneCream.05 mg/gTopicalSandoz2012-07-27Not applicableUs
CalcipotrieneSolution.05 mg/mLTopicalImpax Generics2009-11-20Not applicableUs
CalcipotrieneSolution.05 mg/mLTopicalHi Tech Pharmacal Co., Inc.2014-10-06Not applicableUs
CalcipotrieneOintment50 ug/gTopicalGlenmark Pharmaceuticals Inc.,Usa2010-03-24Not applicableUs
CalcitreneOintment.05 mg/gTopicalTaro Pharmaceuticals U.S.A., Inc.2010-03-24Not applicableUs
International/Other Brands
Daivonex / Dovonex
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Calcipotriene 0.005% and Betamethasone Dipropionate 0.064%Calcipotriol hydrate (50 ug/g) + Betamethasone dipropionate (.5 mg/g)OintmentTopicalSandoz2014-03-31Not applicableUs
Calcipotriene and Betamethasone DipropionateCalcipotriol hydrate (50 ug/g) + Betamethasone dipropionate (.5 mg/g)OintmentTopicalPerrigo New York Inc.2008-06-01Not applicableUs
Dovobet GelCalcipotriol (50 mcg) + Betamethasone (0.5 mg)GelTopicalLeo Pharma2009-01-28Not applicableCanada
Dovobet OintmentCalcipotriol (50 mcg) + Betamethasone (0.5 mg)OintmentTopicalLeo Pharma2001-11-29Not applicableCanada
EnstilarCalcipotriol (50 mcg) + Betamethasone (0.5 mg)Aerosol, foamTopicalLeo Pharma2016-11-11Not applicableCanada
EnstilarCalcipotriol hydrate (50 ug/g) + Betamethasone dipropionate (.5 mg/g)Aerosol, foamTopicalLeo Pharma2015-10-16Not applicableUs
TaclonexCalcipotriol hydrate (50 ug/g) + Betamethasone dipropionate (.643 mg/g)OintmentTopicalWarner Chilcott2008-06-012017-08-09Us
TaclonexCalcipotriol hydrate (50 ug/g) + Betamethasone dipropionate (.5 mg/g)OintmentTopicalPhysicians Total Care, Inc.2010-10-20Not applicableUs
TaclonexCalcipotriol hydrate (50 ug/g) + Betamethasone dipropionate (.5 mg/g)SuspensionTopicalLeo Pharma2008-06-01Not applicableUs
TaclonexCalcipotriol hydrate (50 ug/g) + Betamethasone dipropionate (.5 mg/g)SuspensionTopicalLeo Pharma2008-06-012017-01-20Us
Categories
UNII
143NQ3779B
CAS number
112965-21-6
Weight
Average: 412.6047
Monoisotopic: 412.297745146
Chemical Formula
C27H40O3
InChI Key
LWQQLNNNIPYSNX-UROSTWAQSA-N
InChI
InChI=1S/C27H40O3/c1-17(6-13-25(29)20-8-9-20)23-11-12-24-19(5-4-14-27(23,24)3)7-10-21-15-22(28)16-26(30)18(21)2/h6-7,10,13,17,20,22-26,28-30H,2,4-5,8-9,11-12,14-16H2,1,3H3/b13-6+,19-7+,21-10-/t17-,22-,23-,24+,25-,26+,27-/m1/s1
IUPAC Name
(1R,3S,5Z)-5-{2-[(1R,3aS,4E,7aR)-1-[(2R,3E,5S)-5-cyclopropyl-5-hydroxypent-3-en-2-yl]-7a-methyl-octahydro-1H-inden-4-ylidene]ethylidene}-4-methylidenecyclohexane-1,3-diol
SMILES

Pharmacology

Indication

For the treatment of moderate plaque psoriasis in adults.

Structured Indications
Pharmacodynamics

Calcipotriene is a synthetic analog of vitamin D. In humans, the natural supply of vitamin D depends mainly on exposure to the ultraviolet rays of the sun for conversion of 7-dehydrocholesterol to vitamin D3 (cholecalciferol) in the skin.

Mechanism of action

The precise mechanism of calcipotriol in remitting psoriasis is not well-understood. However, it has been shown to have comparable affinity with calcitriol for the Vitamin D receptor, while being less than 1% as active as the calcitriol in regulating calcium metabolism. The Vitamin D receptor (VDR) belongs to the steroid/thyroid receptor superfamily, and is found on the cells of many different tissues including the thyroid, bone, kindney, and T cells of the immune system. T cells are known to play a role in psoriasis, and it is thought that the binding of calcipotriol to the VDR modulates the T cells gene transcription of cell differentiation and proliferation related genes.

TargetActionsOrganism
UVitamin D3 receptor
antagonist
Human
Absorption

Clinical studies with radiolabeled ointment indicate that approximately 6% (+3%, SD) of the applied dose of calcipotriene is absorbed systemically when the ointment is applied topically to psoriasis plaques or 5% (+2.6%, SO) when applied to normal skin.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Hepatic. Calcipotriene metabolism following systemic uptake is rapid, and occurs via a similar pathway to the natural hormone. The primary metabolites are much less potent than the parent compound.

Route of elimination

The active form of the vitamin, 1,25-dihydroxy vitamin D3 (calcitriol), is known to be recycled via the liver and excreted in the bile. There is evidence that maternal 1,25-dihydroxy vitamin D3 (calcitriol) may enter the fetal circulation, but it is not known whether it is excreted in human milk.

Half life
Not Available
Clearance
Not Available
Toxicity

Topically applied calcipotriene can be absorbed in sufficient amounts to produce systemic effects. Elevated serum calcium has been observed with excessive use of calcipotriene.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Calcipotriol.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Calcipotriol.Experimental
Aluminum hydroxideThe serum concentration of Aluminum hydroxide can be increased when it is combined with Calcipotriol.Approved
BendroflumethiazideBendroflumethiazide may increase the hypercalcemic activities of Calcipotriol.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Calcipotriol.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Calcipotriol.Approved
CalcidiolThe risk or severity of adverse effects can be increased when Calcipotriol is combined with Calcidiol.Approved, Nutraceutical
CalciumThe risk or severity of adverse effects can be increased when Calcium is combined with Calcipotriol.Nutraceutical
Calcium AcetateThe risk or severity of adverse effects can be increased when Calcium Acetate is combined with Calcipotriol.Approved
Calcium CarbonateThe risk or severity of adverse effects can be increased when Calcium Carbonate is combined with Calcipotriol.Approved
Calcium CitrateThe risk or severity of adverse effects can be increased when Calcium Citrate is combined with Calcipotriol.Approved
Calcium glubionateThe risk or severity of adverse effects can be increased when Calcium glubionate is combined with Calcipotriol.Approved
Calcium GluceptateThe risk or severity of adverse effects can be increased when Calcium Gluceptate is combined with Calcipotriol.Approved
Calcium gluconateThe risk or severity of adverse effects can be increased when Calcium gluconate is combined with Calcipotriol.Approved, Vet Approved
Calcium lactateThe risk or severity of adverse effects can be increased when Calcium lactate is combined with Calcipotriol.Approved, Experimental, Vet Approved
Calcium lactate gluconateThe risk or severity of adverse effects can be increased when Calcium lactate gluconate is combined with Calcipotriol.Experimental
Calcium laevulateThe risk or severity of adverse effects can be increased when Calcium laevulate is combined with Calcipotriol.Experimental
Calcium pangamateThe risk or severity of adverse effects can be increased when Calcium pangamate is combined with Calcipotriol.Experimental
Calcium PhosphateThe risk or severity of adverse effects can be increased when Calcium Phosphate is combined with Calcipotriol.Approved
CaseinThe risk or severity of adverse effects can be increased when Casein is combined with Calcipotriol.Approved
ChlorothiazideChlorothiazide may increase the hypercalcemic activities of Calcipotriol.Approved, Vet Approved
ChlorthalidoneChlorthalidone may increase the hypercalcemic activities of Calcipotriol.Approved
CholestyramineThe serum concentration of Calcipotriol can be decreased when it is combined with Cholestyramine.Approved
ColesevelamThe serum concentration of Calcipotriol can be decreased when it is combined with Colesevelam.Approved
ColestipolThe serum concentration of Calcipotriol can be decreased when it is combined with Colestipol.Approved
CyclopenthiazideCyclopenthiazide may increase the hypercalcemic activities of Calcipotriol.Experimental
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Calcipotriol.Approved, Investigational
CymarinCymarin may decrease the cardiotoxic activities of Calcipotriol.Experimental
DanazolDanazol may increase the hypercalcemic activities of Calcipotriol.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Calcipotriol.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Calcipotriol.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Calcipotriol.Approved
DihydrotachysterolThe risk or severity of adverse effects can be increased when Calcipotriol is combined with Dihydrotachysterol.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Calcipotriol.Approved, Investigational
DoxercalciferolThe risk or severity of adverse effects can be increased when Calcipotriol is combined with Doxercalciferol.Approved
ErgocalciferolThe risk or severity of adverse effects can be increased when Calcipotriol is combined with Ergocalciferol.Approved, Nutraceutical
GitoformateGitoformate may decrease the cardiotoxic activities of Calcipotriol.Experimental
HydrochlorothiazideHydrochlorothiazide may increase the hypercalcemic activities of Calcipotriol.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the hypercalcemic activities of Calcipotriol.Approved
IndapamideIndapamide may increase the hypercalcemic activities of Calcipotriol.Approved
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Calcipotriol.Experimental
MethyclothiazideMethyclothiazide may increase the hypercalcemic activities of Calcipotriol.Approved
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Calcipotriol.Experimental
MetolazoneMetolazone may increase the hypercalcemic activities of Calcipotriol.Approved
Mineral oilThe serum concentration of Calcipotriol can be decreased when it is combined with Mineral oil.Approved, Vet Approved
OleandrinOleandrin may decrease the cardiotoxic activities of Calcipotriol.Experimental
OrlistatThe serum concentration of Calcipotriol can be decreased when it is combined with Orlistat.Approved, Investigational
OuabainOuabain may decrease the cardiotoxic activities of Calcipotriol.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Calcipotriol.Approved, Vet Approved
ParicalcitolThe risk or severity of adverse effects can be increased when Calcipotriol is combined with Paricalcitol.Approved, Investigational
PeruvosidePeruvoside may decrease the cardiotoxic activities of Calcipotriol.Experimental
PolythiazidePolythiazide may increase the hypercalcemic activities of Calcipotriol.Approved
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Calcipotriol.Experimental
QuinethazoneQuinethazone may increase the hypercalcemic activities of Calcipotriol.Approved
SucralfateThe serum concentration of Sucralfate can be increased when it is combined with Calcipotriol.Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Calcipotriol.Approved, Investigational
TrichlormethiazideTrichlormethiazide may increase the hypercalcemic activities of Calcipotriol.Approved, Vet Approved
Food Interactions
Not Available

References

Synthesis Reference

Andrzej Kutner, Michal Chodynski, Teresa Ryznar, Hanna Fitak, Jerzy Winiarski, Bartlomiej Gorecki, Agnieszka Burzynska, Wieslaw Szelejewski, "Process for Preparation of Pharmaceutically Pure Anhydrous Calcipotriol." U.S. Patent US20080214876, issued September 04, 2008.

US20080214876
General References
Not Available
External Links
Human Metabolome Database
HMDB15567
KEGG Drug
D01125
PubChem Compound
5288783
PubChem Substance
46507122
ChemSpider
4450880
BindingDB
50369964
ChEBI
50749
ChEMBL
CHEMBL1200666
Therapeutic Targets Database
DAP000292
PharmGKB
PA448714
IUPHAR
2778
Guide to Pharmacology
GtP Drug Page
HET
MC9
RxList
RxList Drug Page
Wikipedia
Calcipotriol
ATC Codes
D05AX02 — CalcipotriolD05AX52 — Calcipotriol, combinations
AHFS Codes
  • 84:06.00 — Anti-inflammatory Agents
  • 84:92.00 — Misc. Skin and Mucous Membrane Agents
PDB Entries
1s19

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedTreatmentActinic Keratosis (AK)1
1CompletedOtherPsoriasis1
1CompletedOtherPsoriasis Vulgaris1
1CompletedTreatmentPlaque Type Psoriasis1
1CompletedTreatmentPsoriasis Vulgaris2
1RecruitingOtherPsoriasis1
1RecruitingTreatmentPsoriasis1
1RecruitingTreatmentScalp Psoriasis1
1WithdrawnTreatmentScleroderma1
1, 2CompletedTreatmentArthritis / Psoriasis1
1, 2CompletedTreatmentPsoriasis2
1, 2CompletedTreatmentPsoriasis / Psoriasis Vulgaris1
2CompletedTreatmentAtopic Dermatitis (AD)1
2CompletedTreatmentHand Eczema1
2CompletedTreatmentPlaque Psoriasis2
2CompletedTreatmentPlaque-Type Psoriasis1
2CompletedTreatmentPsoriasis Vulgaris3
2Unknown StatusTreatmentRadiodermatitis1
2, 3CompletedTreatmentNail Psoriasis1
2, 3CompletedTreatmentPsoriasis1
2, 3Unknown StatusTreatmentAcne Vulgaris1
3CompletedTreatmentPsoriasis1
3CompletedTreatmentPsoriasis Vulgaris3
3Not Yet RecruitingTreatmentNail Psoriasis2
3Not Yet RecruitingTreatmentPsoriasis1
4CompletedTreatmentPlaque Psoriasis1
4CompletedTreatmentPsoriasis3
4CompletedTreatmentPsoriasis Vulgaris1
4RecruitingTreatmentPlaque Psoriasis1
4TerminatedTreatmentPlaque Psoriasis1
Not AvailableCompletedNot AvailablePlaque Psoriasis2
Not AvailableCompletedTreatmentChronic Plaque Psoriasis1
Not AvailableCompletedTreatmentPsoriasis1
Not AvailableRecruitingNot AvailablePsoriasis Vulgaris1
Not AvailableTerminatedBasic ScienceMorphoea / Scleroderma, Localized1
Not AvailableUnknown StatusTreatmentDermatitis, Allergic Contact1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Dosage forms
FormRouteStrength
CreamTopical.05 mg/g
OintmentTopical.05 mg/g
OintmentTopical50 ug/g
SolutionTopical.05 mg/mL
GelTopical
CreamTopical50 ug/g
CreamTopical50 mcg
OintmentTopical50 mcg
SolutionTopical50 mcg
Aerosol, foamTopical
Aerosol, foamTopical50 ug/g
OintmentTopical
Spray, meteredTopical
SuspensionTopical
Prices
Unit descriptionCostUnit
Dovonex 0.005% Cream 120 gm Tube607.03USD tube
Dovonex 0.005% Solution 60ml Bottle323.98USD bottle
Dovonex 0.005% Cream 60 gm Tube303.51USD tube
Dovonex 0.005% cream4.23USD g
Dovonex 50 mcg/ml Solution0.84USD ml
Dovonex 50 mcg/g Cream0.83USD g
Dovonex 50 mcg/g Ointment0.81USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5763426No1995-06-092015-06-09Us
US6753013No2000-01-272020-01-27Us
US6787529No2000-01-272020-01-27Us
US8263580No2008-09-272028-09-27Us
US8629128No2006-05-262026-05-26Us
US9119781No2011-06-102031-06-10Us

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0135 mg/mLALOGPS
logP4.63ALOGPS
logP3.84ChemAxon
logS-4.5ALOGPS
pKa (Strongest Acidic)14.39ChemAxon
pKa (Strongest Basic)-1.6ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area60.69 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity125.45 m3·mol-1ChemAxon
Polarizability49.59 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9945
Blood Brain Barrier+0.8426
Caco-2 permeable+0.7643
P-glycoprotein substrateSubstrate0.7718
P-glycoprotein inhibitor INon-inhibitor0.7297
P-glycoprotein inhibitor IINon-inhibitor0.9687
Renal organic cation transporterNon-inhibitor0.813
CYP450 2C9 substrateNon-substrate0.8383
CYP450 2D6 substrateNon-substrate0.8975
CYP450 3A4 substrateSubstrate0.7113
CYP450 1A2 substrateNon-inhibitor0.7455
CYP450 2C9 inhibitorNon-inhibitor0.7898
CYP450 2D6 inhibitorNon-inhibitor0.9336
CYP450 2C19 inhibitorNon-inhibitor0.7994
CYP450 3A4 inhibitorNon-inhibitor0.8014
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7475
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.9332
BiodegradationNot ready biodegradable0.9871
Rat acute toxicity3.9699 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9198
hERG inhibition (predictor II)Non-inhibitor0.8018
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as vitamin d and derivatives. These are compounds containing a secosteroid backbone, usually secoergostane or secocholestane.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Vitamin D and derivatives
Direct Parent
Vitamin D and derivatives
Alternative Parents
Triterpenoids / Secondary alcohols / Cyclic alcohols and derivatives / Hydrocarbon derivatives
Substituents
Triterpenoid / Cyclic alcohol / Secondary alcohol / Organic oxygen compound / Hydrocarbon derivative / Organooxygen compound / Alcohol / Aliphatic homopolycyclic compound
Molecular Framework
Aliphatic homopolycyclic compounds
External Descriptors
seco-cholestane, hydroxy seco-steroid (CHEBI:50749) / Vitamin D3 and derivatives (LMST03020106)

Targets

Details
1. Vitamin D3 receptor
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Zinc ion binding
Specific Function
Nuclear hormone receptor. Transcription factor that mediates the action of vitamin D3 by controlling the expression of hormone sensitive genes. Recruited to promoters via its interaction with BAZ1B...
Gene Name
VDR
Uniprot ID
P11473
Uniprot Name
Vitamin D3 receptor
Molecular Weight
48288.64 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Peroxidase activity
Specific Function
Part of the host defense system of polymorphonuclear leukocytes. It is responsible for microbicidal activity against a wide range of organisms. In the stimulated PMN, MPO catalyzes the production o...
Gene Name
MPO
Uniprot ID
P05164
Uniprot Name
Myeloperoxidase
Molecular Weight
83867.71 Da
References
  1. Sato H, Ogino Y, Takagi H, Hata J, Asano S, Ohta T, Komoriya K: Pharmacological profiles of high-concentration (20 microg/g) tacalcitol ointment: effects on cutaneous inflammation, epidermal proliferation, and differentiation in mice. J Dermatol. 2003 Jul;30(7):510-24. [PubMed:12928540]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxidoreductase activity
Specific Function
Has a role in maintaining calcium homeostasis. Catalyzes the NADPH-dependent 24-hydroxylation of calcidiol (25-hydroxyvitamin D(3)) and calcitriol (1-alpha,25-dihydroxyvitamin D(3)). The enzyme can...
Gene Name
CYP24A1
Uniprot ID
Q07973
Uniprot Name
1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial
Molecular Weight
58874.695 Da
References
  1. Jones G, Byford V, West S, Masuda S, Ibrahim G, Kaufmann M, Knutson JC, Strugnell S, Mehta R: Hepatic activation and inactivation of clinically-relevant vitamin D analogs and prodrugs. Anticancer Res. 2006 Jul-Aug;26(4A):2589-95. [PubMed:16886668]

Drug created on June 13, 2005 07:24 / Updated on October 21, 2017 19:30